N-benzyl-3,3-dimethylbutan-1-imine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-3,3-dimethylbutan-1-imine
• 英文别名: N-(3,3-dimethylbutyl)-1-phenylmethanimine
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: STECCGVGUYBWAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-benzyl-3,3-dimethylbutan-1-imine 在 盐酸 、 碳酸氢钠 、 氯甲酸苯酯 作用下， 以 四氢呋喃 、 甲基叔丁基醚 、 水 为溶剂， 反应 2.0h， 生成 1-(3,3-二甲基丁基)-3-(2-氟-4-甲基-5-(4,4,5,5-四甲基-1,3,2-二氧硼戊烷-2-基)苯基)脲
  参考文献：
  名称：

  Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

  摘要：

  The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mutation, Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with RAS mutations in preclinical models and are contraindicated for treatment of cancer patients with BRAF WT background, including patients with KRAS or NRAS Mutation. In order to eliminate the issues associated with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with RAS mutant cancers, we sought to identify a compound not only active against BRAF V600E but also wild. type BRAF and CRAF. On the basis of its superior in vitro and in vivo profile, compound 13 was selected for further development and is currently being evaluated in phase I clinical studies.

  DOI：

  10.1021/acs.jmedchem.5b00067
• 作为产物：
  描述：

  N-benzyl-3,3-dimethylbutanamide 在 chlorobis(cyclooctene)-iridium(I) dimer 、 二乙基硅烷 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 N-benzyl-3,3-dimethylbutan-1-imine
  参考文献：
  名称：

  铱和手性硫脲顺序催化对仲酰胺的对映选择性还原氰化和膦酰基化

  摘要：

  过渡金属催化和有机催化的结合为化学家提供了实现各种前所未有的化学转化的机会。通过将铱与手性硫脲催化结合，首次实现了仲酰胺的直接对映选择性还原性氰化和膦酰化，以合成富含对映体的手性α-氨基腈和α-氨基膦酸酯。该方案高效且对映选择性良好，为从简单易得的原料合成旋光性α-官能化胺提供了一条新颖的途径。另外，反应是可扩展的，并且硫脲催化剂可以再循环和再利用。

  DOI：

  10.1002/anie.202015898

文献信息

• [EN] 2-AMINO, 6-PHENYL SUBSTITUTED PYRIDO [2, 3 - D] PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 2-AMINO, 6-PHENYL À SUBSTITUTION PYRIDO [2, 3 - D] PYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RAF KINASE
  申请人：LILLY CO ELI

  公开号：WO2013134243A1

  公开（公告）日：2013-09-12

  The present invention provides the compound l-(3,3-Dimethylbutyl) -3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea or a pharmaceutically acceptable salt thereof, that inhibits Raf and, therefore, may be useful in treating cancer.

  本发明提供了一种化合物l-(3,3-二甲基丁基)-3-(2-氟-4-甲基-5-(7-甲基-2-(甲基氨基)吡啶[2,3-d]嘧啶-6-基)苯基)脲或其药用可接受的盐，该化合物能抑制Raf，因此可能用于治疗癌症。
• Anti-Markovnikov Intermolecular Hydroamination:  A Bis(amidate) Titanium Precatalyst for the Preparation of Reactive Aldimines
  作者：Zhe Zhang、Laurel L. Schafer

  DOI：10.1021/ol0359214

  日期：2003.11.1

  [reaction: see text] A bulky bis(N-2',6'-diisopropylphenyl(phenyl)-amidate)titanium-bis(diethylamido) complex was identified as a highly active and regioselective precatalyst for the anti-Markovnikov hydroamination of a wide range of terminal alkyl alkynes with alkylamines. This titanium complex was fully characterized, including its X-ray crystal structure. The reactive aldimine products generated

  [反应：见正文]大量的双（N-2'，6'-二异丙基苯基（苯基）-氨基甲酸酯）钛-双（二乙基酰胺基）配合物被确定为一种高活性和区域选择性的催化剂，可用于广泛的抗马尔可夫尼科夫加氢胺化反应范围的末端烷基炔烃与烷基胺。该钛配合物已得到充分表征，包括其X射线晶体结构。使用一锅法进一步精制了生成的反应性醛亚胺产品，以提供取代的胺，醛和异喹啉骨架。
• Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells
  作者：James R. Henry、Michael D. Kaufman、Sheng-Bin Peng、Yu Mi Ahn、Timothy M. Caldwell、Lakshminarayana Vogeti、Hanumaiah Telikepalli、Wei-Ping Lu、Molly M. Hood、Thomas J. Rutkoski、Bryan D. Smith、Subha Vogeti、David Miller、Scott C. Wise、Lawrence Chun、Xiaoyi Zhang、Youyan Zhang、Lisa Kays、Philip A. Hipskind、Aaron D. Wrobleski、Karen L. Lobb、Julia M. Clay、Jeffrey D. Cohen、Jennie L. Walgren、Denis McCann、Phenil Patel、David K. Clawson、Sherry Guo、Danalyn Manglicmot、Chris Groshong、Cheyenne Logan、James J. Starling、Daniel L. Flynn

  DOI：10.1021/acs.jmedchem.5b00067

  日期：2015.5.28

  The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mutation, Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with RAS mutations in preclinical models and are contraindicated for treatment of cancer patients with BRAF WT background, including patients with KRAS or NRAS Mutation. In order to eliminate the issues associated with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with RAS mutant cancers, we sought to identify a compound not only active against BRAF V600E but also wild. type BRAF and CRAF. On the basis of its superior in vitro and in vivo profile, compound 13 was selected for further development and is currently being evaluated in phase I clinical studies.
• Enantioselective Reductive Cyanation and Phosphonylation of Secondary Amides by Iridium and Chiral Thiourea Sequential Catalysis
  作者：Dong‐Huang Chen、Wei‐Ting Sun、Cheng‐Jie Zhu、Guang‐Sheng Lu、Dong‐Ping Wu、Ai‐E Wang、Pei‐Qiang Huang

  DOI：10.1002/anie.202015898

  日期：2021.4.12

  and phosphonylation of secondary amides have been accomplished for the first time for the synthesis of enantioenriched chiral α‐aminonitriles and α‐aminophosphonates. The protocol is highly efficient and enantioselective, providing a novel route to the synthesis of optically active α‐functionalized amines from the simple, readily available feedstocks. In addition, the reactions are scalable and the

  过渡金属催化和有机催化的结合为化学家提供了实现各种前所未有的化学转化的机会。通过将铱与手性硫脲催化结合，首次实现了仲酰胺的直接对映选择性还原性氰化和膦酰化，以合成富含对映体的手性α-氨基腈和α-氨基膦酸酯。该方案高效且对映选择性良好，为从简单易得的原料合成旋光性α-官能化胺提供了一条新颖的途径。另外，反应是可扩展的，并且硫脲催化剂可以再循环和再利用。